acute liver failure / 10.3
alcoholic cirrhosis / 8.6
alpha-1-antitrypsin deficiency / 1.4
autoimmune hepatitis / 1.0
biliary atresia / 0.7
Budd Chiari syndrome / 2.1
cryptogenic cirrhosis / 5.5
familial amyloidotic polyneuropathy / 1.0
HBV HCV related cirrhosis / 0.3
HBV related cirrhosis / 4.5
HCC / 19.6
HCV related cirrhosis / 5.5
intrahepatic CCC / 0.7
M. Osler / hemangioma / 0.3
neuroendocrine metastases / 1.0
Other / 0.7
Oxalose / 0.3
PBC / 2.7
polycystic disease / 3.4
PSC / 8.2
re-TX: biliary complications / 3.4
re-TX: chronic graft failure / 5.5
re-TX: chronic rejection / 1.0
re-TX: primary graft non-function / 6.2
re-TX: recurrent viral hepatitis / 0.3
re-TX: vascular complications / 2.4
secondary biliary cirrhosis / 1.7
Wilson disease / 1.4
Total: / 100.0
Supplementary Table 1:Shown are the indications for liver transplantation in the study population (HBV = hepatitis b; HCV = hepatitis c; re-Tx = retransplantation).
Causes of death: / %cardiovascular event / 12.5
cerebral: bleeding / 2.5
cerebral: ischemia / 5.1
data not available / 2.6
de novo malignancy / 3.8
gastrointestinal: ischemia / 3.8
gastrointestinal: perforation / 2.5
Infection: fungal / 6.3
Infection: sepsis / 21.5
intraabdominal bleeding / 5.1
liver graft: biliary tract complications / 12.7
liver graft: initial graft non-function / 2.5
lung: ARDS / 8.9
lung: pneumonia / 3.8
polytrauma / 1.3
social: suicide / 1.3
tumor recurrence / 3.8
Total: / 100.0
Supplementary Table 2: Shown are the most probable causes of death in our study population (HBV = hepatitis B; HCV = hepatitis C; ARDS = Acute Respiratory Distress Syndrome).
PRBC (units) / 0 / 1-5 / 6-10 / 11-15 / >16Cases (n) / 3 / 50 / 96 / 53 / 89
HM
(Chi2/MWU) / 0%
(n.s./n.s.) / 8.0 %
(p=0.027/p=0.027) / 13.5 %
(n.s./n.s.) / 17.0 %
(n.s./n.s.) / 33.7 %
(p<0.001/p<0.001)
30-DM
(Chi2/MWU) / 0%
(n.s./n.s.) / 4.0 %
(p=0.042/p=0.042) / 10.4 %
(n.s./n.s.) / 5.7 %
(n.s./n.s.) / 24.7 %
(p<0.001/p<0.001)
3-MM
(Chi2/MWU) / 0%
(n.s./n.s.) / 6.0 %
(p=0.005/p=0.005) / 16.7 %
(n.s./n.s.) / 17.0 %
(n.s./n.s.) / 36.0 %
(p<0.001/p<0.001)
Cases (n) / 3 / 45 / 79 / 44 / 62
PTHD
(Chi2/MWU) / 0%
(n.s./n.s.) / 16.0 %
(p<0.001/p<0.001) / 36.5 %
(p=0.009/p=0.009) / 47.2 %
(n.s./n.s.) / 78.7 %
(p<0.001/p<0.001)
ESRD
(Chi2/MWU) / 0%
(n.s./n.s.) / 8.0 %
(p=0.031/p=0.031) / 11.5 %
(p=0.023/p=0.023) / 17.0 %
(n.s./n.s.) / 34.8 %
(p<0.001/p<0.001)
FFP (units) / 0 / 1-5 / 6-10 / 11-15 / >16
Cases (n) / 2 / 13 / 75 / 69 / 168
HM
(Chi2/MWU) / 0%
(n.s./n.s.) / 7.7 %
(n.s./n.s.) / 12.0 %
(n.s./n.s.) / 16.0 %
(n.s./n.s.) / 13.1 %
(p=0.002/p=0.002)
30-DM
(Chi2/MWU) / 0%
(n.s./n.s.) / 7.7 %
(n.s./n.s.) / 10.7 %
(n.s./n.s.) / 10.1 %
(n.s./n.s.) / 9.5 %
(n.s./n.s.)
3-MM
(Chi2/MWU) / 0%
(n.s./n.s.) / 23.1 %
(n.s./n.s.) / 14.7 %
(n.s./n.s.) / 17.4 %
(n.s./n.s.) / 16.1 %
(p=0.025/p=0.025)
Cases (n) / 2 / 12 / 62 / 59 / 141
PTHD
(Chi2/MWU) / 0%
(n.s./n.s.) / 30.8 %
(n.s./n.s.) / 42.7 %
(n.s./n.s.) / 42.0 %
(n.s./n.s.) / 41.1 %
(p=0.011/p=0.011)
ESRD
(Chi2/MWU) / 0%
(n.s./n.s.) / 15.4 %
(n.s./n.s.) / 13.3 %
(n.s./n.s.) / 13.0 %
(n.s./n.s.) / 12.5 %
(p=0.001/p=0.001)
Platelets (units) / 0 / 1-2 / 3-4 / >4
Cases (n) / 98 / 81 / 53 / 59
HM
(Chi2/MWU) / 8.2%
(p=0.001/p=0.001) / 12.3%
(n.s./n.s.) / 20.8%
(n.s./n.s.) / 45.8%
(p<0.001/p<0.001)
30-DM
(Chi2/MWU) / 6.1%
(p=0.016/p=0.001) / 7.4%
(n.s./n.s.) / 11.3%
(n.s./n.s.) / 32.2%
(p<0.001/p<0.001)
3-MM
(Chi2/MWU) / 12.2%
(p=0.012/p=0.012) / 14.8%
(n.s./n.s.) / 20.8%
(n.s./n.s.) / 42.4%
(p<0.001/p<0.001)
Cases (n) / 91 / 68 / 41 / 33
PTHD
(Chi2/MWU) / 18.4%
(p<0.001/p<0.001) / 43.2%
(n.s./n.s.) / 64.2%
(p=0.007/p=0.007) / 86.4%
(p<0.001/p<0.001)
ESRD
(Chi2/MWU) / 6.1%
(p<0.001/p<0.001) / 12.3%
(n.s./n.s.) / 18.9%
(n.s./n.s.) / 49.2%
(p<0.001/p<0.001)
Supplementary Table 3: Shown are the influences of different amounts of units of transfused packed red blood cells (PRBC), fresh frozen plasma (FFP) and platelets on hospital mortality (HM), 30-day mortality (30-DM), 3-month mortality (3-MM), the necessity of postoperative hemodialysis (PTHD) and the development of end-stage renal disease (ESRD).
AKIN stage / n / %0 / 68 / 29.2
1 / 69 / 29.6
2 / 36 / 15.5
3 / 60 / 25.8
Total: / 233 / 100,0
Supplementary Table 4: Shown are the AKIN stages of renal injury for those patients without pre-transplant renal replacement therapy within the first 48 h after the first cut in liver transplantation (n=233). 56 of 291 patients were on renal replacement therapy prior to liver transplantation or retransplantation. These patients were excluded from analysis of renal outcome after transplantation.